rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Measuring Choroidal Thickness Using Optical Coherence Tomography
Status: Not yet recruiting

To compare the choroidal thickness in eyes of diabetic patients with eyes of age matched controls using optical coherence tomography.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  All known Type 2 DM patients aged 30 to 95 years either gender who presented to ophthalmology clinics in Assuit ophthalmology hospital with no history of ocular treatment (ocular treatment naïve) and visual acuity of 0.1 (6/60) or more that are able to complete an eye examination, and non-diabetic healthy individuals (HbA1c <7) will be included in the study.  Exclusion Criteria:  Known diagnosis of any other retinal disease, glaucoma, neurodegenerative disease, and any significant media opacities that precluded fundus imaging and not giving consent will be excluded. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 30 Years - MaximumAge: 95 Years - StdAgeList: Adult, Older Adult - StudyPopulation: known Type 2 DM patients aged 30 to 95 years either gender with no history of ocular treatment and non-diabetic healthy individuals who come to the hosoital - SamplingMethod: Non-Probability Sample
Biodex Balance System in Patients With Parkinson's Disease
Status: Recruiting

Conventional balance exercises are an effective rehabilitation method applied in routine rehabilitation programs for Parkinson's patients. With technological developments, balance exercises

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Parkinson's diagnosis and Hoehn Yahr stage I-III Not changing medical treatment in the last three months Mini mental test score is over twenty-four  Exclusion Criteria:  Vestibular hypofunction Neurological disease other than Parkinson's disease (multiple sclerosis, stroke, myopathy) History of lower extremity surgery (such as arthroplasty, anterior cruciate ligament repair) Upper limb amputation in the participant Impairment in cognitive functions History of psychotic illness Presence of stage 4 gonarthrosis history of malignancy - HealthyVolunteers: No - Gender: All - MinimumAge: 40 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult
Virtual Reality in Patients With Knee Osteoarthritis
Status: Recruiting

One of the main challenges facing the therapist in the treatment of adhesive capsulitis is to motivate the patient throughout conventional therapy. As noted in a recent review, individuals are more interested in leisure activities rather than performing repetitive tasks during therapy. Virtual reality (VR) is a three-dimensional computer-aided programme built with a system that creates virtual reality movements and generates a high amount of visual and sensory feedback during exercise. As a result, virtual reality (VR) has been used in many medical indications and has been shown to promote adherence to treatment by increasing patient motivation.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Diagnosis of chronic (>3 months) knee osteoarthritis between the ages of 40-85 Kellgren and Lawrence Score ≥ 2 on knee radiograph Visual Analogue scale result VAS 4-8  Exclusion Criteria:  Orthopedic surgery performed on the lower extremity Cognitive dysfunction (Mini Mental Test Score <23) Having received any treatment for knee osteoarthritis in the last 6 months Following any ongoing exercise program (tai chi, pilates, yoga, fitness) History of ligament and ligament injury around the knee - HealthyVolunteers: No - Gender: All - MinimumAge: 40 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
Tolerability and Efficacy of Adjuvant T-DM1 in Patients With HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents. Real-world Multicenter Retrospective-prospective Study
Status: Recruiting

Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Histological diagnosis of HER2 positive breast cancer; Presence of invasive residual disease on T or N after neoadjuvant chemotherapy including anti-HER2 agents Treatment with T-DM1 in the adjuvant post-neoadjuvant setting, in case of positive hormone receptors in combination with adjuvant hormone therapy. Complementary radiotherapy will be allowed as per lines guide; Availability of adequate information regarding treatment with adjuvant T-DM1 in accordance with the objectives of the study; Written informed consent for the prospective part and, if possible, for the recruited patients retrospectively  Exclusion Criteria:  Concomitant treatments with other biological agents; Absence of clinical data that allow the correct analysis of the primary and secondary objectives; Patients with a history of other malignant neoplasms; Contraindications to the use of T-DM - HealthyVolunteers: No - Gender: Female - StdAgeList: Child, Adult, Older Adult - StudyPopulation: HER2 positive breast cancer - SamplingMethod: Non-Probability Sample
Suprascapular Nerve Block in Patients Rehabilitated After Arthroscopic Rotator Cuff Repair
Status: Recruiting

Suprascapular nerve block is an injection method that has been shown to be effective in shoulder rehabilitation in diseases such as adhesive capsulitis and stroke .. Applying the block under USG guidance instead of blinding increases the effectiveness and reduces complications.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  -Having undergone arthroscopic rotator cuff repair surgery within the last week  Exclusion Criteria:  History of previous surgery on the same shoulder History of systemic inflammatory rheumatological disease Neurological diseases with muscle weakness in the upper extremity (MS, ALS, Muscular -Dystrophy) History of malignancy, pregnancy, breastfeeding Use of steroids or immunosuppressive drugs History of allergic reactions to local analgesics Fibromyalgia syndrome Chronic painful conditions that require opioid use Presence of known psychiatric disease Cognitive impairment (Mini Mental Test Score <23) - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Forced Oscillation and Breathing Pattern in Asthma
Status: Not yet recruiting

Asthma is a chronic respiratory disease characterised by airway inflammation, bronchoconstriction, and airway hyperresponsiveness. Accurate and reliable assessment of lung function is crucial in diagnosing and monitoring asthma. The forced oscillation technique (FOT) is a non-invasive method that has gained attention in recent years as a valuable tool for evaluating respiratory mechanics in asthma.

FOT involves applying small amplitude oscillations at various frequencies to the respiratory system and measuring the resulting pressure and flow responses. These measurements provide valuable insights into the mechanical properties of the airways, including resistance, compliance, and reactance. FOT offers several advantages over traditional spirometry, such as its ability to assess peripheral airway function, sensitivity to small airway abnormalities, and ease of use, particularly in young children or individuals with severe airflow limitation. FOT also allows for assessment of respiratory mechanics in individuals who may struggle with performing spirometry manoeuvres.

However, it is unclear whether a change in breathing pattern in patients with obstructive lung disease impacts the assessment of a response to treatment utilising FOT.

Several studies have demonstrated a high prevalence of Breathing Pattern Disorders (BPDs) in individuals with asthma. These findings suggest that BPDs may be common in asthma and could contribute to the manifestation and severity of respiratory symptoms. Evidence suggests that BPDs can adversely affect pulmonary function in individuals with asthma. One study demonstrated that children with asthma and dysfunctional breathing exhibited significantly reduced forced expiratory volume in one second (FEV1) compared to asthmatics without BPD. This suggests that abnormal breathing patterns may contribute to airflow limitation in asthma, leading to decreased lung function.

We therefore wish to determine the impact of different breathing frequencies on parameters measured using FOT in patients diagnosed with asthma and concomitant obstructive lung function abnormality.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age > 18years Confirmed diagnosis of asthma Evidence of obstructive lung disease, FEV1/forced vital capacity (FVC) <lower limit of normal (LLN)  Exclusion Criteria:  Unstable/Uncontrolled asthma, as designated by the patient's consultant Known breathing pattern disorder Inability to cooperate with instructions Refusal to give informed consent - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with physician-diagnosed asthma and demonstrable obstructive lung disease. - SamplingMethod: Non-Probability Sample
Development of a Remote Therapy Protocol for Upper Limb Function Enhancement in Children With Cerebral Palsy
Status: Not yet recruiting

The perpose of this study: Development and demonstration of a teletherapy protocol to improve upper limb function in children with cerebral palsy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 6 to 12 years MACS level 1-4 Diagnosed with CP due to central nervous system lesions  Exclusion Criteria:  Individuals with a Manual Ability Classification System (MACS) level V, indicating an inability to use both hands in daily life activities. Individuals who fall within levels 0 to 4 of the House Functional Classification System. Individuals with severe intellectual disabilities, characterized by difficulties in understanding or following instructions. Individuals with vision impairment that could affect participation in the therapy. Individuals who have received a botulinum toxin injection in the upper extremity within the past 6 months. - HealthyVolunteers: No - Gender: All - MinimumAge: 6 Years - MaximumAge: 12 Years - StdAgeList: Child
Reprieve System Pilot Study
Status: Recruiting

The objective of the study is to evaluate the use of the Reprieve System to decongest subjects with acute decompensated heart failure.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom (dyspnea, orthopnea, or edema/swelling) AND 1 sign (peripheral edema, ascites, jugular venous distension, pulmonary vascular congestion on chest radiography) ≥10 lb. (4.5 kg) above dry weight either by historical weights or as estimated by health care provider. Patients ≥ 18 years of age able to provide informed consent and comply with study procedures.  Exclusion Criteria:  Inability to place Foley catheter or IV catheter or other urologic issues that would predispose the patient to a high rate of urogenital trauma or infection with catheter placement. Hemodynamic instability as defined by any of the following: systolic blood pressure <90 mmHg, use of vasopressors, use of IV inotropes to treat hypotension (systolic blood pressure <90 mm Hg) or suspected/confirmed low cardiac output/shock, mechanical circulatory support, uncontrolled arrhythmias, active severe bleeding, or confirmed or suspected cardiogenic shock. Note: In the absence of the above conditions, use of inotropes to augment diuresis is permitted. Dyspnea due primarily to non-cardiac causes (e.g., severe chronic obstructive pulmonary disease or pneumonia). Acute infection with evidence of systemic involvement (e.g., clinically suspected infection with fever or elevated serum white blood cell count). Estimated glomerular filtration rate (eGFR) < 20 ml/min/1.73m2 calculated using the MDRD equation or current use of renal replacement therapy (RRT). Significant left ventricular outflow obstruction, uncorrected complex congenital heart disease, known severe stenotic valvular disease, infiltrative or constrictive cardiomyopathy, acute myocarditis, type 1 acute myocardial infarction requiring treatment (within previous week), or any other pathology that, in the opinion of the investigator, would make aggressive diuresis poorly tolerated. Inability to follow instructions or comply with follow-up procedures. Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures. Severe baseline electrolyte abnormalities (e.g., serum potassium <3.0 mEq/L, magnesium <1.3 mEq/L or sodium <125 mEq/l). Note: These are based on baseline/screening labs. Subjects whose electrolyte levels are repleted cannot be reassessed for inclusion in the trial. Enrollment in another interventional trial during the index hospitalization Life expectancy less than 3 months Women who are pregnant or intend to become pregnant. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Preliminary Exploration of Thromboelastography in the Monitoring of Anticoagulation in Maintenance Hemodialysis Patients
Status: Recruiting

Objectives: To investigate the role of thromboelastography parameters (R, K, Angle, MA) in monitoring anticoagulation in maintenance hemodialysis (MHD) patients.

Subjects: Two hundred stable MHD patients. Methods: An observational study. Primary outcome: Relationship between thromboelastography parameter R Value and coagulation of hemodialysis circuit and dialyzer.

Secondary outcome: Relationship between thromboelastography parameters (K Value, Angle and MA) and coagulation of hemodialysis circuit and dialyzer.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  male or female patients aged over 18 years stable patients undergoing maintenance hemodialysis treatment for at least 3 months signed informed consent form  Exclusion Criteria:  concomitant with severe diseases such as active malignancy, severe liver diseases, systemic infection, etc. planned or ongoing pregnancy or lactation unsuitable for inclusion in this study after assessment - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: stable patients undergoing maintanence hemodialysis - SamplingMethod: Non-Probability Sample
Corticosteroids in Carpal Tunnel Syndrome. Prospective Randomised Controlled Non-inferiority Study
Status: Recruiting

The goal of this prospective, randomised, controlled, non-inferiority analytical study is to compare the Boston score in patients treated with systemic (intramuscular) versus local infiltration corticosteroids in mild and moderate carpal tunnel syndrome in patients over 18 years of age with mild or moderate carpal tunnel syndrome.

The main questions it aims to answer are:

What is the effectiveness of intramuscular injection of corticosteroids compared to local infiltration in the treatment of mild/moderate carpal tunnel syndrome?
What are the adverse effects and application site pain associated with each route of administration?

Patients who meet the inclusion criteria will be asked to participate in the study and sign an informed consent form.

The Redcap randomizer will be used to assign the patient to one of the branches.

Researchers will compare

Branch A: patients treated with local corticosteroid infiltration in carpal tunnel under ultrasound
Branch B: patients treated with intramuscular corticosteroid injection.

Researchers will:

Compare Boston Carpal Tunnel Questionnaire score at 1.5 months, 3 months, 6 months and 12 months post-procedure.
Describe adverse reactions associated with the route of administration.
Compare the pain at the site of application associated with the route of administration.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients aged 18 years and older Clinical diagnosis of mild/moderate idiopathic Carpal Tunnel Syndrome (paresthesias in the territory of the median nerve: in fingers 1, 2, 3 and radial border of 4 of the hand, nocturnal hand pain, and Positive Tinel's test, or Positive Phalen's test, or Positive Durkan's test) Diagnosis by electromyography and sensory and motor conduction velocity of mild/moderate involvement Patients who have agreed to participate in the study and signed the informed consent form.  Exclusion Criteria:  Cervical radiculopathy, polyneuropathy, brachial plexus pathologies, thoracic operculum syndrome Systemic diseases causing secondary Carpal Tunnel Syndrome (rheumatoid arthritis, diabetes with polyneuropathy, hypothyroidism with low adherence to treatment, chronic renal disease) Chronic corticosteroid therapy or regular use of non-steroidal anti-inflammatory drugs Severe carpal tunnel syndrome: signs of thenar atrophy, daytime pain, sensory deficit in median nerve territory (two-point discrimination test >10mm) Previous history of wrist or distal radius fracture Corticosteroid allergies Pregnancy - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Cumulative and Booster Effects of Multisession Prefrontal tDCS in Adolescents With ASD
Status: Recruiting

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by disturbances in communication, poor social skills, and aberrant behavior. To date, ASD has no known cure, and the disorder remains a highly disabling condition. Recently, transcranial direct-current stimulation (tDCS), a non-invasive brain stimulation technique, has shown great promise as a potentially effective and cost-effective tool for reducing the core symptoms in patients with autism, such as anxiety, aggression, impulsivity, and inattention. Although the preliminary findings in patients with ASD are encouraging, it remains to be determined whether this experimental data can translate into benefits in real life. Further studies are needed to determine the factors that can lengthen the therapeutic effects or cognitive benefits of tDCS, and to determine possible risk factors associated with relapse in patients with ASD. Booster sessions of tDCS is an important component of treatment planning and prognosis and may promote better outcomes to control for resurgence of symptoms. This study has three aims. First, the investigators aim to evaluate the therapeutic effects of tDCS on improving cognitive function in patients with ASD. Second, the investigators aim to better understand the neural mechanisms underlying the neuro-enhancing effects of tDCS in patients with ASD. Third, the investigators aim to assess the effectiveness of booster treatment cycles of tDCS for enhancing cognitive and social functions in individuals with ASD.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Individuals who are confirmed by a clinical psychologist based on the Diagnostic and Statistical Manual of Mental Disorders-5th Ed (DSM-V) criteria of Autism spectrum disorder and structured interview with their parents or primary caregivers on their developmental history using the Autism Diagnostic Interview-Revised (ADI-R).  Exclusion Criteria:  Individuals without a confirmed diagnosis from the clinical psychologist, with a history of other neurological and psychiatric disorders and head trauma, or on psychiatric medication will be excluded from the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 12 Years - MaximumAge: 21 Years - StdAgeList: Child, Adult
Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
Status: Not yet recruiting

Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of tumor mortality in China, posing a serious threat to the lives and health of the Chinese people . At present, non-surgical treatment methods are often used, such as radiofrequency ablation (RFA), Transcatheter arterial chemoembolization (TACE), radiation therapy, and systemic anti-tumor therapy. However, whether it is surgical treatment or non-surgical treatment, commonly used liver cancer related biomarkers in clinical practice during the evaluation of treatment efficacy or regular follow-up of patients include AFP, AFP-L3%, DCP, etc. , but there are no reports on whether AKR1B10 can be used for the efficacy evaluation of these treatment methods.Therefore, this project aims to explore the clinical value of AKR1B10 in evaluating the efficacy of liver cancer treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age between 18 and 80 diagnosis of HCC according the AASLD criteria TACE is planned resection is impossible No significant underlying medical illness affecting patient's survival Patients available for regular follow-up according to the study protocol  Exclusion Criteria:  Previous history of other tumors; Combined with other tumors; Received external treatment before admission; Patients who have received blood transfusions within one month; The patient was unable to participate in this study for other reasons. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult - StudyPopulation: All participants have signed an informed consent form, agreeing that their samples and related information can be used for all medical studies. - SamplingMethod: Probability Sample